Analysts have been eager to weigh in on the Healthcare sector with new ratings on Day One Biopharmaceuticals (DAWN – Research Report), Biogen (BIIB – Research Report) and Neurocrine (NBIX – Research Report).
Day One Biopharmaceuticals (DAWN)
In a report released yesterday, Alec Stranahan from Bank of America Securities maintained a Sell rating on Day One Biopharmaceuticals, with a price target of $10.00. The company’s shares closed last Tuesday at $16.64, close to its 52-week high of $17.85.
According to TipRanks.com, Stranahan is a 3-star analyst with an average return of
Day One Biopharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $35.67.
See today’s best-performing stocks on TipRanks >>
Biogen (BIIB)
Bank of America Securities analyst Geoff Meacham maintained a Hold rating on Biogen yesterday and set a price target of $260.00. The company’s shares closed last Tuesday at $193.18, close to its 52-week low of $189.44.
According to TipRanks.com, Meacham is a 4-star analyst with an average return of
Currently, the analyst consensus on Biogen is a Moderate Buy with an average price target of $285.86, representing a 47.9% upside. In a report issued on April 11, J.P. Morgan also maintained a Hold rating on the stock with a $240.00 price target.
Neurocrine (NBIX)
In a report released yesterday, Tazeen Ahmad from Bank of America Securities maintained a Buy rating on Neurocrine, with a price target of $159.00. The company’s shares closed last Tuesday at $140.09, close to its 52-week high of $148.37.
According to TipRanks.com, Ahmad is a 1-star analyst with an average return of
Currently, the analyst consensus on Neurocrine is a Moderate Buy with an average price target of $153.81, which is a 9.1% upside from current levels. In a report issued on April 11, Stifel Nicolaus also maintained a Buy rating on the stock with a $165.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on DAWN:
- Day One’s OJEMDA™ (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain Tumor
- Day One Biopharmaceuticals price target raised to $36 from $32 at JPMorgan
- Day One Biopharmaceuticals trading resumes
- Day One Biopharmaceuticals trading halted, volatility trading pause
- Day One Biopharmaceuticals price target lowered to $33 from $35 at Wedbush
